
==== Front
Clin Transl Med
Clin Transl Med
10.1002/(ISSN)2001-1326
CTM2
Clinical and Translational Medicine
2001-1326
John Wiley and Sons Inc. Hoboken

10.1002/ctm2.1788
CTM21788
Review
Review
RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathy
SHEN et al.
Shen Jinze 1
Shentu Jianqiao 1
Zhong Chenming 2
Huang Qiankai 1
Duan Shiwei https://orcid.org/0000-0001-7682-2877
1 duansw@hzcu.edu.cn

1 Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province School of Medicine Hangzhou City University Hangzhou China
2 Medical Genetics Center, School of Medicine Ningbo University Ningbo China
* Correspondence
Shiwei Duan, Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, China.
Email: duansw@hzcu.edu.cn

07 9 2024
9 2024
14 9 10.1002/ctm2.v14.9 e178815 7 2024
03 4 2024
19 7 2024
© 2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Alternative splicing of pre‐mRNA is a fundamental regulatory process in multicellular eukaryotes, significantly contributing to the diversification of the human proteome. RNA‐binding fox‐1 homologue 2 (RBFOX2), a member of the evolutionarily conserved RBFOX family, has emerged as a critical splicing regulator, playing a pivotal role in the alternative splicing of pre‐mRNA. This review provides a comprehensive analysis of RBFOX2, elucidating its splicing activity through direct and indirect binding mechanisms. RBFOX2 exerts substantial influence over the alternative splicing of numerous transcripts, thereby shaping essential cellular processes such as differentiation and development.

Main body of the abstract

Dysregulation of RBFOX2‐mediated alternative splicing has been closely linked to a spectrum of cardiovascular diseases and malignant tumours, underscoring its potential as a therapeutic target. Despite significant progress, current research faces notable challenges. The complete structural characterisation of RBFOX2 remains elusive, limiting in‐depth exploration beyond its RNA‐recognition motif. Furthermore, the scarcity of studies focusing on RBFOX2‐targeting drugs poses a hindrance to translating research findings into clinical applications.

Conclusion

This review critically assesses the existing body of knowledge on RBFOX2, highlighting research gaps and limitations. By delineating these areas, this analysis not only serves as a foundational reference for future studies but also provides strategic insights for bridging these gaps. Addressing these challenges will be instrumental in unlocking the full therapeutic potential of RBFOX2, paving the way for innovative and effective treatments in various diseases.

RNA‐binding fox‐1 homologue 2 (RBFOX2) binds to RNA, influencing splicing and recruiting PRC2 for transcriptional repression. RBFOX2 impacts electromyographic signalling, L‐type Ca2+ channels, sliding filaments and mitochondria. RBFOX2 is involved in tumour cell proliferation, invasion, migration and drug resistance. Targeting RBFOX2 with compounds, such as T‐1101 tosylate and RNA‐PROTACs, shows promise for treating related diseases. CTD, C‐terminal domain; PRC2, polycomb repressive complex 2; PROTAC, proteolysis‐targeting chimeras; RRM, RNA‐recognition motif. Created with BioRender.com.

alternative splicing
pre‐mRNA
RBFOX2
therapeutic targeting
Qiantang Scholars Fund in Hangzhou City University210000‐581835 source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:07.09.2024
Shen J , Shentu J , Zhong C , Huang Q , Duan S . RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathy. Clin Transl Med. 2024;e1788. 10.1002/ctm2.1788

Jinze Shen and Jianqiao Shentu contributed equally to this work.
==== Body
pmc1 INTRODUCTION

RNA‐binding proteins (RBPs) play pivotal roles in orchestrating RNA‒protein interactions, governing all facets of RNA metabolism from its inception to its degradation. 1 These multifaceted proteins harbour diverse RNA‐binding domains (RBDs), enabling them to recognise a spectrum of short RNA elements and auxiliary non‐RBDs. 2 RBPs exhibit the capability to identify and interact with particular RNA sequences via their respective RBDs. This interaction facilitates a spectrum of crucial cellular processes, encompassing alternative splicing, polyadenylation, nuclear export, intracellular localisation, degradation and regulation of translation. 3

Within the lineage of evolutionarily conserved RBPs, the RBFOX family emerges as a pivotal regulator, particularly notable for its role in modulating alternative pre‐mRNA splicing. This regulatory function is especially pronounced in the developmental contexts of brain, heart and muscle tissue. 4 The RBFOX family has been elucidated as a central player in orchestrating the alternative splicing program of numerous genes, underscoring its pivotal role in mediating tissue‐specific regulatory processes. 5 The gene for one prominent member of this family, RNA‐binding fox‐1 homologue 2 (RBFOX2), alternatively known as RNA‐binding motif protein 9 (RBM9), is situated on the negative strand of chromosome 22q12.3 (hg38 chr22:35738736‐36028824), encompassing a total gene length of 290 089 bp. Mirroring the behaviour of other RBFOX proteins, RBFOX2 predominantly influences spliced isoform expression through its modulation of alternative splicing events in target gene exons. 4 Recent investigations have unveiled RBFOX2's pivotal regulatory roles across multiple biological processes, including cell proliferation, 6 invasion, migration 7 and excitation‒contraction (E‒C) coupling. 8 Perturbed RBFOX2 expression has been correlated with the onset and progression of various malignancies 9 and cardiovascular disorders. 10 Simultaneously, aberrations in RBFOX2 have been implicated in conferring resistance to anticancer drugs, such as tamoxifen (TAM) 11 and Rebecsinib. 6

As a central player in the realm of splicing regulation, a potential biomarker and a therapeutic target for a multitude of disease‐associated genes, RBFOX2 holds substantial promise for research endeavors. While studies pertaining to RBFOX2 are steadily on the rise, there is a conspicuous dearth of comprehensive reviews elucidating its molecular regulatory mechanisms and proposing targeted therapeutic strategies under both physiological and pathological conditions. Consequently, this article aims to systematically synthesise knowledge about RBFOX2, pinpoint the advancements and lacunae in current research, and furnish a directional compass and theoretical framework for ensuing investigations in this field.

2 ELUCIDATING THE PROTEIN DOMAIN ARCHITECTURE AND TRANSCRIPT PROFILE OF RBFOX2

RBFOX constitutes a class of alternative splicing regulators that have endured through mammalian evolution. 5 Currently, researchers have identified three proteins within the RBFOX family: RBFOX1, RBFOX2 and RBFOX3. 12 All members of the RBFOX family share a relatively conserved RNA‐recognition motif (RRM), which exhibits a high‐affinity binding capacity for the hexanucleotide sequence (U)GCAUG (Figure 1). 12 , 13 These RRMs are indispensable for the specific recognition of RNA sequences by RBFOX family proteins. 12 Simultaneously, beyond its recognition of the (U)GCAUG sequence, the RRM of RBFOX has demonstrated an additional capacity to bind to the GCACG sequence. However, it is noteworthy that its binding affinity towards GCACG is comparatively diminished when juxtaposed with (U)GCAUG. 14 Intriguingly, the functionality of RBFOX proteins extends beyond this motif, as they can be indirectly recruited to RNA through participation in the formation of larger assemblies known as large assembly of splicing regulator (LASR) complexes, and can even exhibit splicing activity in the absence of the (U)GCAUG motif. 15

FIGURE 1 Decoding RNA‐binding fox‐1 homologue 2 (RBFOX2): insights into structure, function and RNA‐binding conformation. (A) Primary structure of RBFOX2: the protein sequence of RBFOX2 is compared with its family proteins RBFOX1 and RBFOX3. Notably, the sequences of the RNA‐recognition motif (RRM) and nuclear localisation signal (NLS) are identical in RBFOX2 and RBFOX1. (B) Comparison of RRM between RBFOX2 and RBFOX1: a detailed comparison of the RRM between RBFOX2 and RBFOX1 highlights their structural similarities. (C) RNA‐binding conformation of RBFOX1 with UGCAUGU motif: the RNA‐binding conformation of RBFOX1 with the UGCAUGU motif is depicted. Within this motif, Phe126 plays a crucial role in binding U1, G2, C3 and A4, while His120, Phe158 and Phe160 are essential for binding U5, G6 and U7. Protein structure data utilised in this analysis is sourced from the Protein Data Bank (2CQ3 and 2ERR) and visualised using ChimeraX. 16 (D) Various transcripts of human RBFOX2 depict a complex exon organisation, where constitutive exons are delineated by orange boxes, alternative exons by grey‒blue boxes, and regions potentially untranslated by red gradients. Exon numbering serves for precise identification, correlating with genomic coordinates detailed in Table S1. We numbered the RBFOX2 exons with Arabic numerals based on the order of their starting sites on the chromosome. Alternative exons were numbered with letters according to their starting sites on the chromosome. This splicing procedure ensures that each exon has a unique identifier, allowing for a clearer description of the gene structure and alternative splicing forms. It is important to note that this exon numbering may not align with previously reported exon designations (coordinate information of RBFOX2 exons based on GRCh38/hg38).

Furthermore, within the RBFOX family, it has been observed that both RBFOX1 and RBFOX2 proteins possess a conserved nuclear localisation signal (NLS) situated in the C‐terminal domain (CTD). 13 This NLS plays a pivotal role in ensuring strong nuclear localisation of RBFOX family proteins under non‐stress conditions. 17 Under stress conditions, RBFOX family proteins show cytoplasmic localisation mediated by stress granules. 18 When cells are under stress, numerous proteins and RNAs aggregate in the cytoplasm to form non‐enveloped structures known as stress granules. 19 RBFOX family proteins strongly bind to stress granules through their RRM, thereby shifting from nuclear to cytoplasmic localisation. 18 Alterations in the subcellular localisation of these proteins are intimately connected to changes in their capacity to regulate alternative splicing. 20 It is worth noting that aside from the RRM and NLS regions, the remaining sequences of RBFOX proteins display limited conservation. 13

In addition to their structural features, RBFOX family coding genes can generate a multitude of distinct transcripts through alternative splicing of RRM coding domains and some exons, which affects their subcellular localisation and regulatory functions in alternative splicing. 21 RBFOX2 comprises 14 exons and 13 introns, generating a total of 20 transcripts, 15 of which have protein‐coding potential. Different transcripts can be translated to produce protein isoforms with varying splicing activities. For example, exon 6 encodes 31 of the 73 residues of the RBFOX2 RRM. 22 Skipping exon 6 eliminates β‐strand 3 and α‐helix 2 from the RBFOX2 structure. β‐Strand 3 contains the key RNP1 motif for RRM folding and has several crucial RNA contact sites. 12 Thus, exon 6 is key to the structural integrity of RBFOX2 RRM, and its omission will completely alter the protein's conformation and RNA‐binding ability. In‐depth study of the RBFOX2‐ΔRRM isoform revealed that RBFOX2‐ΔRRM not only lost its RNA binding activity but also inhibited the alternative splicing function of other RBFOX2 proteins containing a complete RRM. Therefore, scientists classified these RBFOX2 isoforms that act in a dominant negative (DN) manner as DN subtypes. 22 Different transcripts also produce protein isoforms with different subcellular localisations. For example, exon 9 contains a 5‐amino acid coding sequence (Ser‐Leu‐Pro‐Leu‐Val) associated with RBFOX2 subcellular localisation. By including this peptide, RBFOX2 can translocate from the nucleus to the cytoplasm. 23 Deletion of RBFOX2 exon 10 likely causes a frameshift, resulting in the RBFOX2‐ΔE10 isoform, which contains a PTEVT amino acid sequence at the C‐terminus, causing migration to the cytoplasm. 24 , 25 In addition, different transcripts of RBFOX2 are closely related to its indirect binding mode mediated by the LASR complex, which can further affect the splicing activity of RBFOX2. For example, a pair of 43 and 40 nt exons in the CTD coding sequence are specific for encoding muscle (RBFOX2‐43) and non‐muscle isoforms (RBFOX2‐40) of RBFOX2, respectively. The 40 nt exon‐encoded peptide chain contains three tyrosine residues, which are crucial for RBFOX2 to participate in the assembly of LASR. 26 , 27 However, muscle isoforms (RBFOX2‐43) lack these tyrosine residues and cannot function through the indirect binding mode, resulting in limited splicing activity. 26

Distinguished from other RBFOX family proteins, RBFOX2's unique CTD orchestrates the recruitment of the polycomb repressive complex 2 (PRC2) to target genes. 28 RBFOX2 also acts as a reader recognising specific epigenetic marks on RNA, such as N6‐methyladenosine (m6A) 29 and 5‐hydroxymethylcytosine (hm5C). 30 The PRC2‐mediated histone modification (H3K27me3) plays a crucial role in the aberrant silencing of downstream genes 28 and is a feature observed across diverse cell types in mammals. 31 When RBFOX2 engages with chromatin‐associated RNAs (caRNAs), it acts as a mediator for the recruitment of the PRC2 complex. Consequently, the PRC2 complex induces histone methylation within the gene promoter region, effectively inhibiting transcription. 28 In a recent breakthrough, researchers discovered that RBFOX2 recognises m6A modification on caRNAs. 29 RBFOX2 demonstrates a specific ability to recognise and bind m6A modifications on caRNAs, precisely by virtue of its RRM's recognition of the AGm6AUG sequence. 29 This event subsequently prompts RBFOX2 to enlist RBM15, a constituent of the methyltransferase complex, to modify promoter‐associated RNAs with m6A. The interaction between RBM15 and the m6A reader YTHDC1 facilitates the recruitment of YTHDC to the site where RBFOX2 binds. Ultimately, YTHDC ushers in the PRC2 complex to the same locus as RBFOX2, thereby instigating H3K27me3 histone modifications at neighboring promoter sites, culminating in transcriptional repression. 28 , 29 , 32 When RBFOX2 acts as a reader of m6A, it plays an important role in acute myeloid leukaemia (AML). Overexpressed RBFOX2 inhibits the expression of TGFB1 through the RBFOX2/m6A/RBM15/YTHDC1/PRC2 axis, blocks the transforming growth factor‐beta (TGF‐β) signalling pathway, and promotes the progression of AML. Downregulation of RBFOX2 significantly inhibits the survival and proliferation of AML cells and promotes myeloid differentiation. RBFOX2 is essential for the self‐renewal and stemness maintenance of AML cells, making it a potential target for leukaemia treatment. 29 Additionally, Dou et al. found that RBFOX2 can act as a reader of RNA hm5C, exerting specific recognition and degradation functions on target genes. Specifically, the methyltransferase NSUN5 first acts as a writer to introduce m5C modification on the caRNA of CTNNB1, which encodes β‐catenin. NSUN5 then recruits TET2 and RBFOX2 to chromatin. Under the action of TET2, m5C on caRNA is converted to hm5C. Wu et al.’s study first discovered that RBFOX2 can act as a reader of hm5C to inhibit the expression of CTNNB1. However, the specific molecular mechanism by which RBFOX2 inhibits the expression of CTNNB1 has not yet been explored. One possibility is that, similar to its role as a reader of m6A, RBFOX2 regulates the expression of target genes by recruiting the PRC2 complex. This requires further in‐depth research. 30 This synergistic function of RBFOX2 complements its role in transcriptional repression by recruiting PRC2, indicating that RBFOX2 can act as a multifunctional protein coordinating its interaction with multiple targets. 30

3 UNRAVELING THE VERSATILE FUNCTIONS AND MODES OF ACTION OF RBFOX2 IN ALTERNATIVE SPLICING REGULATION

Alternative splicing is a pivotal determinant of the intricate complexity of multicellular eukaryotic transcriptomes. Its global and gene‐specific regulation governs a wide spectrum of processes, encompassing tissue specificity, cell differentiation and the onset of cancer. 33 Among the family of RBFOX proteins, RBFOX2, akin to its counterparts, plays a central role primarily within the nucleus as a splicing regulator. 34

As detailed in Table 1 and illustrated in Figure 2, recent studies conducted over the past few years have revealed RBFOX2's exceptional capacity to discern unique alternatively spliced RNAs across various tissues. 24 , 35 Leveraging its intrinsic RRM and its specific binding to the (U)GCAUG sequence, RBFOX2 can selectively engage target RNA molecules. 12 Interestingly, not all RBFOX2 splicing targets adhere to the (U)GCAUG motif. 28 In instances where a complete (U)GCAUG sequence is absent, RBFOX2 employs an indirect approach by recruiting other RBPs to execute splicing functions. 15 , 36 Thus, the functions of RBFOX2 are categorised into two distinct modes based on its binding strategies: direct binding modes requiring the (U)GCAUG recognition sequence, 13 and indirect binding modes that rely on the recruitment by additional proteins. 15 , 36

TABLE 1 Alternative splicing (AS) function of RNA‐binding fox‐1 homologue 2 (RBFOX2).

Level	Disease	Gene	Exon	AS	Ref.	
CVD	Hypertension	Cacna1c	9′	Exon skipping	37	
33	Exon inclusion	
Heart failure	Enah	13	Exon inclusion	38	
Sorbs2	4	Exon inclusion	
Cardiomyopathy	MICU1	5′	Exon inclusion	39	
Tpm1	6a	Exon skipping	40	
9b	Exon inclusion	10	
CHD	Atp2b1	21	Exon inclusion	41	
Mef2a	9	Exon inclusion	
Cancer	Lymphoma	ARNT	5	Exon inclusion	42	
NPC	GOLIM4	7	Exon inclusion	32	
GBM	PTBP2	10	Exon inclusion	43	
Ewings sarcoma	ADD3	14	Exon skipping	44	
Endometrial cancer	TFRC	4	Exon inclusion	45	
Laryngeal cancer	MENA	11a	Exon skipping	46	
BrC	NFYA	3	Exon inclusion	47	
BrC/GC	TEAD1	6	Exon inclusion	48	
HCC	Numb	12	Exon inclusion	49	
INSR	11	Exon inclusion	50	
PDAC	MPRIP	23	Exon inclusion	51	
MYL6	6	Exon inclusion	
CLSTN1	10	Exon inclusion	
Others	Hepatitis	Scarb1	12	Exon skipping	52	
Scleroderma	LH2	13A	Exon inclusion	53	
Abbreviations: BrC, breast cancer; CHD, coronary heart disease; CVD, cardiovascular disease; GBM, glioblastoma multiforme; GC, gastric cancer; HCC, hepatocellular cancer; NPC, nasopharyngeal carcinoma; PDAC, pancreatic ductal adenocarcinoma.

John Wiley & Sons, Ltd.

FIGURE 2 RNA‐binding fox‐1 homologue 2 (RBFOX2) splicing modes: direct and indirect binding mechanisms unraveled. In the direct binding mode, RBFOX2 specifically recognises target RNA sequences containing the (U)GCAUG motif through its inherently conserved RNA‐recognition motif (RRM). When RBFOX2 binds upstream of a target exon splice site, it consistently leads to exon skipping. Conversely, binding downstream of the splice site results in exon inclusion. In the indirect binding mode, RBFOX2 interacts with target RNA indirectly by binding to other RNA‐binding proteins (RBPs). This interaction enables RBFOX2 to cross‐link with the target RNA, allowing it to exert splicing activity regardless of whether the RNA sequence contains the complete (U)GCAUG motif or not. PBD, protein‐binding domain; RBD, RNA‐binding domain; RBP, RNA‐binding protein; RRM, RNA‐recognition motif. Created with BioRender.com.

In the direct binding mode, RBFOX2 exhibits a remarkable ability to specifically recognise and bind both primary splicing factor binding sequences (GCAUG) and secondary splicing factor binding sequences (GCCUG or GCUUG) through its conserved RRM, subsequently localising to the target splicing site. 36 , 51 RBFOX2 typically targets introns in precursor mRNA (pre‐mRNA), 50 3′ untranslated regions (UTRs) in mRNA, 54 and even pre‐miRNA. 55 Notably, when RBFOX2 binds downstream binding sites of a target exon, exon inclusion is typically promoted, whereas binding upstream binding sites of a target exon inhibits exon inclusion. 6 Due to the variable promoter and alternative splicing events that can diversify RBFOX2 gene products, the structure of RBFOX2's RRM is particularly susceptible to disruption. Consequently, RBFOX2 subtypes can be classified into RBFOX2‐wild type (WT) with an intact RRM and RBFOX2‐DN subtypes lacking a complete RRM. 22 Dysregulation of any RBFOX2 subtype in humans can lead to aberrant splicing in related genes and subsequent disease manifestations. 7 , 56 Notably, the isoforms of the RBFOX gene can also be modulated by other RBPs; for instance, overexpression of CELF1 triggers a transition from the RBFOX2‐WT isoform to the RBFOX2‐40 isoform (an RBFOX2‐DN isoform). 26 Certain subtypes of other RBFOX family members have been observed to influence RBFOX2's RRM, giving rise to RBFOX2‐DN subtypes. 22 , 57 In mice, for instance, the Rbfox3 can impede exon 6 inclusion in Rbfox2 pre‐mRNA, causing an in‐frame deletion of RRM and the consequent emergence of the Rbfox2‐DN isoform. 22 Certain sno‐lncRNAs, such as SNORD116, exhibit the ability to recruit and form complexes with RBFOX2. This interaction impedes the nuclear migration of RBFOX2, consequently attenuating its role in modulating alternative splicing within the nucleus. 58

In the indirect binding mode, RBFOX2 forms associations with target RNA indirectly through interactions with other RBPs. 36 For example, RBFOX2 can be recruited by SRSF1, which binds within or downstream of a target exon, thereby participating in alternative splicing without directly engaging the target RNA. 36 Similarly, the RBPs recruiting RBFOX2 for indirect RNA binding may also comprise one or more components of a protein complex. Notably, hnRNP M within the LASR complex, a splicing complex, has been identified as an RBFOX2 recruiter, enhancing RBFOX2's binding to target genes. 36 RBFOX2 can be indirectly recruited to cross‐linking sites by directly binding to hnRNP M as part of the LASR complex, 15 allowing it to cross‐link with target RNA with or without a complete (U)GCAUG motif and to facilitate splicing activity. 15 Recent studies have even unveiled RBFOX2's recruitment by the smooth muscle‐specific regulator RBPMS, forming a distinct, cell‐specific splicing regulatory complex distinct from LASR. 59

Recent studies have shown that in addition to producing different mRNA transcripts through alternative splicing, another outcome of RBFOX2 splicing is the induction of nonsense‐mediated RNA decay (NMD). NMD is an mRNA surveillance pathway that recognises and selectively degrades transcripts containing premature termination codons (PTCs), preventing the production of incomplete or abnormal proteins. 60 RBFOX2 can introduce PTCs into its downstream mRNA through alternative splicing, causing these mRNAs to be degraded via the NMD pathway. This gene regulation mode, where alternative splicing is coupled with NMD, is also called AS‐NMD. 61 NMD plays an important role in the expression of RBPs. 62 As shown in study by Jangi et al., RBPs are particularly enriched in genes regulated by RBFOX2 through AS‐NMD. 61 These RBPs regulated by RBFOX2 greatly expand its regulatory network. Additionally, since RBFOX2 itself is also an RBP, its mRNA may also be affected by other RBPs in the cell and undergo NMD. This forms a cross‐regulatory competition mechanism between RBFOX2 and other RBPs, wherein they influence each other's expression levels and competitively regulate the expression of downstream genes. This regulatory mechanism increases the complexity of gene expression regulation in cells and may help cells adapt to environmental changes or perform specific functions. 61 , 63

4 DECIPHERING THE INTRICATE REGULATION OF RBFOX2 SUBCELLULAR LOCALISATION

RBFOX1 and RBFOX2 proteins consistently demonstrate strong nuclear localisation under non‐stressed conditions. 17 , 21 This localisation pattern is influenced by alternative splicing events involving the coding sequence of their CTD, giving rise to nuclear localisation isoforms containing NLS and cytoplasmic localisation isoforms devoid of NLS. 4 However, in contrast to RBFOX1 proteins, the nuclear localisation of RBFOX2 is subject to additional, more stringent regulatory mechanisms beyond its conserved C‐terminal NLS. 25

RBFOX2 undergoes transcription from at least four distinct promoters, generating an array of isoforms with diverse properties. 64 Some RBFOX2 isoforms have unique N‐terminal domains (NTD). 25 When a functional NLS is generated within this unique NTD, it can enable certain subtypes to exhibit nuclear localisation in the absence of a C‐terminal NLS. 25 For example, in mouse mammary epithelial cells, there are two Rbfox2 isoforms with different NTDs, Rbfox2‐1A and Rbfox2‐1F. 65 Both isoforms skip or splice exon B40, resulting in frameshifts and the absence of the typical C‐terminal NLS. The NTD of Rbfox2‐1A contains a potential amino acid sequence that functions as a functional NLS, allowing Rbfox2‐1A to show nuclear localisation, unlike Rbfox2‐1F, which shows cytoplasmic localisation. 25

Furthermore, the subcellular localisation of RBFOX2 can also be influenced by isoforms of other RBFOX family members. For instance, during early chick embryo development, the Rbfox3‐Δ31 isoform, characterised by the exclusion of exon 31aa, is notably abundant in the cytoplasm. This specific isoform, Rbfox3‐Δ31, possesses the ability to modulate the splicing activity of Rbfox2 by altering its subcellular localisation. 34

Since post‐transcriptional regulation steps usually occur in specific subcellular compartments, such as the nucleus, mitochondria and Golgi apparatus, 66 abnormal subcellular localisation can theoretically affect the activity of RBFOX2 as a splicing factor in the nucleus, potentially leading to pathological changes. 25 Under normal nuclear localisation, RBFOX2 regulates RNA splicing by binding to pre‐mRNA, essential for developing and maintaining tissues such as the brain, 35 muscle 67 and heart. 68 The translocation of RBFOX2 to the cytoplasm may regulate its activity as a splicing factor in the nucleus, closely linked to neuronal degeneration, 69 muscle atrophy 70 and congenital heart disease. 54 This translocation is also associated with various malignant phenotypes of tumour cells, such as enhanced cell proliferation, inhibited apoptosis, invasion and migration. 25 , 51

5 RBFOX2 AND CARDIOVASCULAR DISEASE AND HEALTH

Cardiovascular disease (CVD) stands as a formidable global health challenge, encompassing a spectrum of conditions including cardiomyopathy, coronary heart disease (CHD), hypertension, heart valve disease, arrhythmia, etc. 71 Recent research endeavours have illuminated RBFOX2's potential utility as a diagnostic and prognostic biomarker for CVDs, with mounting evidence linking its dysregulated expression to the onset of these diseases. RBFOX2, through its intricate molecular mechanisms, contributes significantly to the maintenance of myocardial development and function, playing a pivotal role in the physiological and pathological processes that underpin the cardiovascular system.

5.1 RBFOX2 dysregulation in CVDs

The expression profile of RBFOX2 exhibits significant dysregulation across a spectrum of CVDs, as summarised in Table 2. Downregulated RBFOX2 expression characterises conditions, such as dilated cardiomyopathy (DCM) 68 and CHD. 41 , 72 Conversely, diseases marked by elevated RBFOX2 expression include arrhythmia, 26 myotonic dystrophy type 1 (DM1) cardiomyopathy 26 and hypertension. 37 However, the expression of RBFOX2 in diabetic heart disease (DHD) 56 , 73 remains subject to controversy.

TABLE 2 Dysregulated RNA‐binding fox‐1 homologue 2 (RBFOX2) in cardiovascular diseases.

Disease	Expression of RBFOX2	Case	Control	Ref.	
Arrhythmia	Upregulated	3 arrhythmic non‐DM heart samples of DM1 patients	8 autopsied heart samples of normal individuals	26	
DM1 cardiomyopathy	Upregulated	5 autopsied heart samples of DM1 patients	8 autopsied heart samples of normal individuals	26	
DCM	Downregulated	Cardiomyocytes from transverse aortic constriction‐treated mice	Cardiomyocytes from sham‐treated mice	68	
Hypertension	Upregulated	Vascular smooth muscle cells of hypertensive mice	Vascular smooth muscle cells of normal mice	37	
CHD	Downregulated	Whole heart tissue from CHD in mice (established by streptozotocin)	Whole heart tissue from normal mice (injected daily with citrate buffer)	41	
Downregulated	172 surgically discarded cardiovascular tissues	172 surgically discarded cardiovascular tissues	72	
DHD	Downregulated	Cardiomyocytes from diabetic mice (fed with high‐fat diet)	Cardiomyocytes from normal mice (fed with standard diet)	56	
	Upregulated	Cardiomyocytes from type 2 diabetic human left ventricles	Cardiomyocytes from non‐diabetic human left ventricles	73	
Abbreviations: CHD, coronary heart disease; DCM, dilated cardiomyopathy; DHD, diabetic heart disease; DM1, myotonic dystrophy type 1.

John Wiley & Sons, Ltd.

In a CHD model established using streptozotocin, Rbfox2 expression is significantly reduced in whole heart tissues. 41 Similar observations are made in cardiovascular tissues from CHD patients, where RBFOX2 expression is markedly decreased compared to normal samples. 72 Wei et al. deleted the Rbfox2 gene by crossing 129S6/SVEvTac mice, with LoxP sites flanking Rbfox2 exons 6 and 7, with Mlc2v‐Cre transgenic mice, using the Cre‐LoxP recombinase system. Compared to normal mice, the heart sections of Rbfox2 conditional deletion mice exhibited significant ventricular enlargement and thinning of the ventricular wall, ultimately developing into typical DCM. Notably, their results confirmed that Rbfox2 deletion leads to DCM, which subsequently causes heart failure, indicating that downregulation of Rbfox2 is not merely a functional consequence of heart failure. 68

Notably, the upregulation of RBFOX2 is often associated with a specific isoform, the RBFOX2‐DN isoform. In DHD, RBFOX2 expression is elevated in left ventricular cardiomyocytes of human patients with type 2 diabetes mellitus, and this upregulation coincides with increased expression of RBFOX2‐DN isoforms. 73 Similarly, Rbfox2 expression is increased in rat vascular smooth muscle cells (VSMCs) and upregulated in hypertensive arteries, accompanied by enhanced expression of DN subtypes. 37 In heart samples from patients with DM1 cardiomyopathy or DM1 non‐diabetic arrhythmia, RBFOX2 upregulation is coupled with the selective upregulation of the RBFOX2‐40 isoform (a type of RBFOX2‐DN). 26

However, paradoxically, a recent study reveals that Rbfox2 expression is downregulated in the heart tissue of diabetic rats induced by high‐fat feeding compared to the control group. 56 Despite this downregulation, the levels of Rbfox2‐DN exhibit a clear upward trend, aligning with previous findings. 73 This suggests that upregulation of RBFOX2‐DN isoforms is a consistent phenomenon in diabetic hearts. Nonetheless, the overall up‐ or downregulation of RBFOX2 levels may be governed by changes in other isoforms, influenced by distinct disease states.

Furthermore, the subcellular localisation of RBFOX2 varies within different cell types. In isolated rat VSMCs and rat mesenteric artery smooth muscle cells, Rbfox2 predominantly localises to the nucleus. 37 In contrast, in hypoplastic left heart syndrome (HLHS), RBFOX2 is primarily cytoplasmic in the hearts of HLHS patients. 54 Thus, the ectopic expression of RBFOX2 emerges as a hallmark feature of cardiovascular cytopathies.

5.2 RBFOX2 affects cardiovascular health and disease

Cardiac dysfunction constitutes a significant contributor to CVDs, encompassing a spectrum of issues ranging from L‐type calcium channel CaV1.2 function to defects in cardiac E‒C coupling and mitochondrial integrity (Figure 3). 56 , 74 An increasing body of research underscores the pivotal role of RBFOX2 as a key regulatory factor in myocardial E‒C coupling, Cav1.2 channel function, and the maintenance of mitochondrial morphology. RBFOX2 emerges as a critical player in preserving normal myocardial development and overall cardiovascular health.

FIGURE 3 RNA‐binding fox‐1 homologue 2 (RBFOX2): orchestrating cardiomyocyte function. RBFOX2 plays a pivotal role in regulating physiological mechanisms closely associated with cardiomyocyte function, such as excitation‒contraction coupling (E‒C coupling), calcium ion channels and mitochondrial metabolism, by influencing the alternative splicing of downstream genes. Dysregulation of RBFOX2 has been implicated in the onset of various cardiovascular diseases, including arrhythmias and cardiomyopathy. Specifically, RBFOX2 can promote the expression of Jph2 by inhibiting the maturation of miR‐34a, thereby enhancing the conduction of electrical signals in cardiomyocytes. RBFOX2 also inhibits the inclusion of Cacna1c exon 9′, thereby stabilising the number of L‐type calcium channels in cardiomyocyte membranes and promoting calcium transients after depolarisation. Additionally, RBFOX2 promotes the inclusion of MICU1 exon 5′, enhancing mitochondrial Ca2+ uptake and thereby boosting energy metabolism. RBFOX2 also facilitates the inclusion of Enah exon 13, Sorbs2 exon 4 and Tpm1 exon 9b, while inhibiting the inclusion of Tpm1 exon 6a, thus promoting muscle fibre contraction. EI, exon inclusion; EMG, electromyographic; ES, exon skipping. Created with BioRender.com.

Cardiac E‒C coupling orchestrates the transition from electrical excitation to muscle fibre contraction, underpinning proper cardiac function. 8 While Jph2 variants have been linked to diverse cardiac disorders, the mechanisms underlying these associations have remained elusive. 75 , 76 Recent findings in neonatal rat cardiomyocytes shed light on this conundrum, demonstrating that reduced Rbfox2 levels trigger the maturation of miR‐34a. miR‐34a, in turn, targets and inhibits the expression of Jph2, resulting in E‒C coupling defects that culminate in impaired cardiac contraction and, ultimately, heart failure. 8 , 38

The Cav1.2 channel, encoded by the CACNA1C gene, represents a critical substrate for cardiac electrophysiological activity. 77 It participates in E‒C coupling, modulates action potential duration, regulates cardiac cell gene expression and plays a central role in cardiac function. 78 Aberrant Cav1.2 channel activity can induce premature depolarisation of cardiomyocytes, leading to severe arrhythmias and sudden cardiac death. 79 In hypertensive rat VSMCs, elevated Rbfox2 inhibits the inclusion of Cacna1c exon 9′ and promotes the inclusion of exon 33. Notably, Cacna1c exon 9′ and exon 33 exert differential regulation over various biochemical and physiological functions of Cacna1c. 80 , 81 , 82 Furthermore, exon 9′ has been shown to play a pivotal role in the contraction of cerebral arteries. 83 Consequently, dysregulation of Rbfox2's influence on Cav1.2 channel function emerges as a key contributor to hypertension pathogenesis. 37 Cacna1c is the gene encoding Cav1.2, a critical subtype of the L‐type calcium channel in cardiomyocytes. In diabetic rats, when RBFOX2 is downregulated by advanced glycation end‐products, it promotes the inclusion of Cacna1c exon 9′ and the expression of Cav1.2. Upon sarcolemma depolarisation, Ca2+ enters the cell through membrane‐bound Cav1.2, inducing calcium‐induced calcium release from the sarcoplasmic reticulum into the cytoplasm. Downregulation of RBFOX2 leads to excessive Cav1.2 on the membrane, resulting in excessive Ca2+ in the sarcoplasm, continuous contraction of muscle fibres, and subsequent myocardial hypertrophy in diabetic patients. 56

Mitochondria are pivotal in sustaining cardiac energy metabolism, with preserving their intact morphology forming the bedrock of their functionality. 84 Mitochondrial abnormalities lead to energy deficits in cardiac tissue, precipitating bioenergetic diseases such as heart failure. 85 Research has elucidated that in H9c2 cells, the gene Slc25a4 possesses two distinct polyadenylation sites, resulting in the generation of mRNA molecules with differing lengths of 3′ UTR. Notably, the mRNA variant featuring an extended 3′ UTR exhibits diminished stability and translation efficiency, thereby impeding Slc25a4 expression. The protein Rbfox2 intervenes in this process by counteracting the influence of the distal polyadenylation site. Through its binding affinity to the UGCAUG motif downstream of the distal polyadenylation site on Slc25a4, Rbfox2 prompts the preferential production of mRNA with a shorter 3′ UTR. Diminishment of Rbfox2 levels results in an elevation of Slc25a4 mRNA harbouring the longer 3′ UTR, consequently dampening Slc25a4 expression. This dysregulation culminates in mitochondrial dysfunction within H9c2 cells, a phenomenon closely linked to cardiomyopathy pathogenesis. 10 , 86 Moreover, during cardiac differentiation, RBFOX2 selectively promotes the inclusion of MICU1 exon 5′, endowing specificity to mitochondrial Ca2+ uptake, a critical component for ATP production during muscle contraction. 39 , 87

In addition, multiple splicing events coordinated by Rbfox2 contribute to myoblast fusion. For example, during myocyte differentiation, Rbfox2 promotes the production of two muscle‐specific isoforms (Mef2d and Rock2) that synergistically control the terminal differentiation of myoblasts into multinucleated myotubes. 88 , 89

In heart failure, reduced mouse Rbfox2 expression inhibits the inclusion of exon 13 in Enah and exon 4 in Sorbs2, while during heart development, 38 mouse Rbfox2 governs the balance by repressing Tpm1 isoforms containing exon 6a 40 and promoting Tpm1 isoforms with exon 9b. 10 Dysregulated splicing patterns of key genes involved in the cGMP‒PKG‒Ca2+ pathway, such as Atp2b1 exon 21 and Mef2a exon 9, heighten the risk of cardiomyopathy and heart failure in patients with CHD and diabetes. 41 In diabetic mouse foetal hearts, the inhibition of the PKC‐mediated activation of Rbfox2 disrupts early developmental homeostasis. 90 Additionally, RBFOX2 influences the alternative splicing of genes like MBNL1, MCAM, VCL and ACTN1, with downstream effects on the differentiation and function of cardiac smooth muscle cells. 91 It is worth noting that the Gazzara et al. confirmed the splicing antagonism between CELF2 and the RBFOX family through knockdown and overexpression experiments in human cells, showing that CELF2 inhibits RBFOX2 mRNA and protein levels. 92 Both CELF2 and RBFOX proteins are involved in the development and maintenance of neurons, muscle and cardiac tissues, and their antagonism contributes to splicing regulation in normal cardiac development and disease. 57 , 93 However, the crosstalk between these proteins has not been directly studied. A deeper understanding of CELF2 and RBFOX2's functional antagonism may explain differences in expression and splicing between muscle and brain.

Given its pivotal role in cardiovascular health, the dysregulation of RBFOX2 can lead to a range of CVDs, including cardiomyopathy 10 and heart failure. 38 Antagomir, a synthetic miRNA inhibitor capable of binding to specific miRNAs, has shown promise in ameliorating heart failure characterised by low Rbfox2 expression. Multiple upregulated cardiac key miRNAs (let‐7f, miR‐16, miR‐200b) in heart failure negatively regulate Rbfox2. However, antagomir cocktail therapy has demonstrated the potential to restore Rbfox2 levels in a mouse cardiomyocyte‐induced heart failure model. 38 Consequently, antagomir presents a potential therapeutic avenue for treating heart failure with a low expression of RBFOX2 phenotype. 38

6 DYSREGULATED RBFOX2 IN CANCER PROGRESSION

Cancer stands as the foremost contributor to global mortality. 94 Within the realm of cancer, RBFOX2 emerges as a potential biomarker, wielded for both diagnostic and prognostic purposes, while its aberrant expression forms an intricate association with the extent of tumour malignancy. Furthermore, RBFOX2 exhibits the capability to foster the phenotypic traits of cancer cells and steer the inexorable march of tumour progression. Notably, RBFOX2 plays a critical role in bolstering the viability of cancer cells even following treatment, thereby constituting a substantial contributing factor to the development of tumour resistance against anticancer therapies.

6.1 RBFOX2 dysregulation and subcellular localisation as diagnostic and prognostic indicators in cancer

In the context of cancer, RBFOX2 undergoes dysregulation at various levels within cells and tissues. Aberrant RBFOX2 expression serves as a valuable biomarker for assessing the malignancy of cancer. Additionally, abnormal subcellular localisation of RBFOX2 holds promise for evaluating the degree of malignancy. As presented in Table 3, cancer types exhibiting elevated RBFOX2 expression encompass lymphoma, 42 uveal melanoma (UM), 95 laryngeal cancer, 46 nasopharyngeal carcinoma (NPC), 32 gastric cancer (GC), 96 colorectal cancer (CRC) 97 and breast cancer (BrC). 7 , 98 Conversely, cancers with reduced RBFOX2 expression include glioblastoma multiforme (GBM) 43 and pancreatic ductal adenocarcinoma (PDAC). 51

TABLE 3 Dysregulated RNA‐binding fox‐1 homologue 2 (RBFOX2) in cancers.

System	Disease	Expression of RBFOX2	Level	Case	Control	Ref.	
Blood system	Lymphoma	Upregulated	Cell	Karpas299 and Jurkat	Primary human T cells	42	
AML	Downregulated	Cell	Paediatric AML‐derived HSCs/HPCs	Non‐leukaemic HSCs/HPCs	6	
Upregulated	Tissue	427 bone marrow samples from GEO database (GSE13159)	73 healthy bone marrow samples from GEO database (GSE13159)	29	
Cell	MM6, MOML13, NOMO1, NB4 and K562	CD34+ HSCs/HPCs from normal human umbilical cord blood		
Nervous system	UM	Upregulated	Tissue	56 UM tissues from the TCGA database and 26 UM tissues from the Rotterdam Ocular Melanoma Study Group	56 UM tissues from the TCGA database and 26 UM tissues from the Rotterdam Ocular Melanoma Study Group	95	
GBM	Downregulated	Tissue	66 anaplastic oligodendroglioma tissues, 145 anaplastic astrocytoma tissues, and 216 GBM tissues from the Brain Tumour Biorepository of the University of Alabama	21 normal brain tissues from the Brain Tumour Biorepository of the University of Alabama	43	
Respiratory system	Laryngeal cancer	Upregulated	Cell	Tu177, Tu212, M4E and Hep2	NP69	46	
NPC	Upregulated	Tissue	Tumour tissues from 20 NPC individuals in Sun Yat‐Sen University Cancer Center	Rhinitis tissues from 19 rhinitis individuals in Sun Yat‐Sen University Cancer Center	32	
Digestive system	GC	Upregulated	Cell	SGC7901, MGC803, BGC823 and AGS	GES1	96	
CRC	Upregulated	Tissue	50 CRC tumour tissue samples	50 normal tissue samples	97	
Upregulated	Tissue	42 CRC tissue samples including from TCGA database	54 normal tissue samples from TCGA database	99	
PDAC	Downregulated	Tissue	PDX model established by injecting metastatic tumour tissue into NOD‐SCID mice	PDX model established by injecting primary tumour tissue into NOD‐SCID mice	51	
Upregulated	Tissue	45 PDAC tissue samples from GEO database (GSE28735)	45 normal tissue samples from GEO database (GSE28735)	100	
Reproductive system	BrC	Upregulated	Cell	MCF7 and HCC1806 in oxygen deficit condition	MCF7 and HCC1806	101	
Upregulated	Tissue	157 TNBC tissues from TCGA database	774 other types of BrC tissues from TCGA database	7	
Abbreviations: AML, acute myeloid leukaemia; BrC, breast cancer; CRC, colorectal cancer; GBM, glioblastoma multiforme; GC, gastric cancer; HPC, haematopoietic progenitor cell; HSC, haematopoietic stem cell; NOD‐SCID, non‐obese diabetic/severe combined immunodeficiency; NPC, nasopharyngeal carcinoma; PDAC, pancreatic ductal adenocarcinoma; PDX, patient‐derived xenograft; TNBC, triple‐negative breast cancer; UM, uveal melanoma.

John Wiley & Sons, Ltd.

In lymphoma, RBFOX2 expression significantly surpasses that in primary human T cells, as evidenced by its higher levels in human lymphoma cells (Karpas299 and Jurkat). 42 Within the UM cohort, analysis of data from TCGA and ROMScohort reveals heightened RBFOX2 expression in patients at higher risk. 95 Laryngeal carcinoma cells (Tu177, M4E, Hep2 and Tu212) show elevated RBFOX2 expression relative to normal nasopharyngeal epithelial cells (NP69) in laryngeal cancer. 46 Furthermore, tumour tissues from NPC patients exhibit significantly higher RBFOX2 levels than mucosal tissues from rhinitis patients. 32 GC cell lines (MCF‐10ASGC7901, MGC803, BGC823 and AGS) manifest increased RBFOX2 expression compared to human normal gastric mucosal epithelial cells (GES1). 96 In CRC, RBFOX2 registers upregulation in cancer tissues compared to normal counterparts. 97 Similarly, in BrC, hypoxia‐treated cell lines (MCF7 and HCC1806) display higher RBFOX2 expression than their normoxia‐treated counterparts. In more malignant BrC patients, specifically those with triple‐negative breast cancer (TNBC), RBFOX2 expression significantly exceeds that in other BrC patients, as indicated by TCGA data. 7 , 101 In contrast, within the context of PDAC, patient‐derived xenograft (PDX) models from metastatic PDAC display reduced RBFOX2 expression relative to PDX models derived from primary PDAC tumour tissue. 51 Moreover, in glioma, RBFOX2 expression is lower in lesion brain tissue of glioma patients compared to normal brain tissue, and within glioma patients, those with higher malignancy exhibit lower RBFOX2 expression in lesion brain tissue than those with less malignancy. 43

The abnormal expression pattern of RBFOX2 in AML remains uncertain. A study utilising the GEO database (GSE13159) revealed that AML patients across various subtypes, including normal karyotype, mixed lineage leukaemia and t(15:17), exhibited significantly elevated RBFOX2 expression in bone marrow samples compared to healthy counterparts. Additionally, Western blot analysis demonstrated higher RBFOX2 expression in five different types of AML cell lines (MM6, MOML13, NOMO1, NB4 and K562) compared to normal human myeloid cell line CD34+ HSCs/HPCs. 29 However, contrasting findings emerged from studies employing fluorescence‐activated cell sorting, indicating that paediatric AML‐derived haematopoietic stem cells (HSCs) and haematopoietic progenitor cells (HPCs) expressed lower levels of RBFOX2 than their cord blood‐derived counterparts. 6 The observed differential expression patterns of RBFOX2 in paediatric AML and adult AML may stem from variances in the splicing events occurring within these distinct contexts. 6 These conflicting results underscore the complexity of RBFOX2 expression regulation in AML and highlight the need for further research to elucidate its role in this context.

It is important to note that RBFOX2 predominantly localises within the nucleus, although its cytoplasmic localisation appears to be cancer cell‐specific. For instance, in CRC, normal colon tissues exhibit nuclear RBFOX2 localisation, whereas strong cytoplasmic RBFOX2 staining is observed in various regions of CRC tissues. Quantitative assessment of nucleoplasmic distribution of RBFOX2 in cells further demonstrates significant differences between normal colon tissue and colon cancer tissue. 97

Furthermore, as delineated in Table 4, RBFOX2 emerges as an independent adverse prognostic factor in various cancer types, including AML, NPC, UM and GC. AML patients exhibiting high RBFOX2 expression demonstrate poorer overall survival. 29 High RBFOX2 expression in NPC is associated with diminished overall survival and disease‐free survival. 32 In UM, elevated RBFOX2 expression correlates with worsened overall survival. 95 In GC, heightened RBFOX2 expression links to advanced clinical and TNM stages, as well as inferior overall survival. 96 , 102 Conversely, in other cancers such as PDAC, hepatocellular cancer (HCC) and GBM, the prognostic implications of RBFOX2 dysregulation contrast with the aforementioned findings. PDAC patients displaying low RBFOX2 expression experience inferior overall survival. 51 Similarly, HCC patients exhibiting low RBFOX2 expression have a poorer overall survival, 49 and GBM patients with reduced RBFOX2 expression encounter diminished overall survival. 43

TABLE 4 The role of RNA‐binding fox‐1 homologue 2 (RBFOX2) in tumour progression.

System	Disease	Effects in vitro	Related cell lines	Effects in vivo	Cancer models	Prognosis	Case	Ref.	
Blood system	AML	Proliferation↓	Paediatric AML‐derived HSCs and HPCs	–	–	–	–	6	
Differentiation↓	NB4	Differentiation↓	CDX model established by injecting MOLM13 cells into NRG‐SGM3 mice	Worse OS	106 AML patients from TCGA database	29	
Motor system	Ewings sarcoma	EMT↑	ASP14	–	–	–	–	44	
Nervous system	GBM	Proliferation↓	U87MG	–	–	Better OS	397 glioma patients from TCGA database	43	
EMT↑	GSC1023 and GSC0910 (glioblastoma stem cell lines derived from GBM patients)	–	–	–	–	103	
Respiratory system	Laryngeal cancer	Proliferation↑, EMT↑ and invasion↑	Tu177 and Hep2	–	–	–	–	46	
NPC	Proliferation↑ and invasion↑	S26 and 5‐8F	Growth↑	CDX model established by injecting S26 cells into BALB/c nude mice	Worse OS and DFS	85 NPC patients from Sun Yat‐Sen University Cancer Center	32	
Digestive system	PDAC	Invasion↓ and migration↓	BxPC3	Metastasis↓	PDX model established by injecting metastatic tumour tissue into NOD‐SCID mice	Better OS	136 primary tumour samples from Sheba Medical Center	51	
Invasion↑ and migration↑	MiaPaCa2, 4039, and Panc1	–	–	–	–	100	
	CRC	Invasion↑ and migration↑	HCT116	–	–	–	–	99	
HCC	–	–	–	–	Better OS	241 HCC patients from Liver Cancer Institute, Zhongshan Hospital, and Beijing 302 Hospital	49	
GC	Proliferation↑	SGC7901 and MGC803	–	–	Worse OS	92 GC patients from the First Affiliated Hospital of Guangzhou University	96	
Proliferation↑, invasion↑ and migration↑	AGS and MKN28	Growth↑ and metastasis↑	CDX model established by injecting MKN45 cells into BALB/c nude mice	Worse OS	50 GC patients from the First Affiliated Hospital of Sun Yat‐sen University	102	
Reproductive system	Endometrial cancer	Ferroptosis↑	KLE and Ishikawa	–	–	–	–	45	
Ovarian cancer	Apoptosis↓	HEY and OVARY1847	–	–	–	–	104	
BrC	EMT↑ and invasion↑	MCF‐7 and HCC‐1806	–	–	–	–	101	
Invasion↑ and migration↑	MCF‐7 and MDA‐MB‐231	–	–	–	–	7	
Invasion↑	MCF‐7 and MDA‐MB‐231	–	–	–	–	105	
Abbreviations: AML, acute myeloid leukaemia; BrC, breast cancer; CDX, cell‐derived xenograft; CRC, colorectal cancer; DFS, disease‐free survival; EMT, epithelial‒mesenchymal transition; GBM, glioblastoma multiforme; GC, gastric cancer; HCC, hepatocellular cancer; NOD‐SCID, non‐obese diabetic/severe combined immunodeficiency; NPC, nasopharyngeal carcinoma; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma.

John Wiley & Sons, Ltd.

6.2 RBFOX2 drives tumour progression

The uncontrolled proliferation and metastasis of tumour cells within the human body represent the primary challenges in the quest to conquer cancer. 106 In recent years, mounting evidence underscores the pivotal role of RBFOX2 in tumour progression. As depicted in Table 4 and Figure 4, RBFOX2 exhibits a nuanced influence on cancer, sometimes promoting tumour proliferation and metastasis, while in other instances, inhibiting these processes.

FIGURE 4 RNA‐binding fox‐1 homologue 2 (RBFOX2): master regulator of cancer cell behaviour. RBFOX2 exerts control over the biological behaviours of diverse cancer cells, including proliferation, epithelial‒mesenchymal transition (EMT), invasion and migration. It achieves this by directly or indirectly modulating the alternative splicing of genes associated with cancer. Imbalances in RBFOX2 expression are implicated in the onset and progression of cancers across various systems, including digestive, respiratory and haematological systems. BrC, breast cancer; CRC, colorectal cancer; EI, exon inclusion; ES, exon skipping; GBM, glioblastoma multiforme; GC, gastric cancer; NPC, nasopharyngeal carcinoma; pAML, paediatric acute myeloid leukaemia; PDAC, pancreatic ductal adenocarcinoma. Created with BioRender.com.

BrC stands out as a highly heterogeneous tumour arising from mammary duct epithelial cells, distinguished by its robust invasive and metastatic potential. 107 , 108 Within BrC cell lines (MCF‐7, HCC‐1806 and MDA‐MB‐231), RBFOX2 significantly bolsters the invasion and migration of cancer cells. 7 , 98 , 105 In hypoxic conditions, TGF‐β signalling upregulates RBFOX2 in BrC cells (MCF‐7 and HCC‐1806), thereby inhibiting ESRP1 at the transcriptional level, consequently fostering the pro‐metastatic MENAΔ11a subtype, enhancing epithelial‒mesenchymal transition (EMT) in BrC cells, and augmenting invasiveness. 101 A lower ESRP1/RBFOX2 ratio has been correlated with increased metastatic risk in BrC patients. 82 Additionally, RBFOX2 modulates Dicer expression via direct interaction with pre‐miR‐107, inhibiting its maturation and subsequently increasing the invasiveness of BrC cell lines. 105 Furthermore, in the more aggressive TNBC, the oncogenic kinase NEK2 stimulates the expression and activity of RBFOX2, thereby promoting the migratory and invasive phenotypes of TNBC cell lines (MDA‐MB‐231). 7

In various other cancer types, RBFOX2 has displayed similar tumour‐promoting functions. For instance, in AML mouse bone marrow cells (MLL‐AF9) and PDX models, Rbfox2 inhibits bone marrow stem cell differentiation. 29 In in vitro cultures of GC cell lines (SGC7901 and MGC803), RBFOX2 overexpression has been shown to enhance the malignant characteristics of GC cells by activating the PI3K/AKT and MAPK signalling pathways. 96 Another study conducted with GC cell lines (AGS and MKN28) revealed that LINC00893 directly binds to RBFOX2, inducing its ubiquitination and degradation. This interaction led to the inhibition of proliferation, migration and invasion of GC cells. 102 Additionally, in a cell‐derived xenograft (CDX) model constructed from MKN45, a GC cell line derived from the gastric lymph nodes of female signet ring cell carcinoma patients, RBFOX2 was found to promote tumour growth and metastasis. 102 These findings underscore the multifaceted role of RBFOX2 in GC progression, shedding light on potential therapeutic avenues. In CRC cells (HCT116), RBFOX2 directly binds to ARHGEF7 pre‐mRNA, promoting the inclusion of cancer‐associated micro‐exons and promoting tumour invasion and migration. 99 In NPC cells (S26 and 5‐8F), RBFOX2 boosts the expression of GOLIM4‐L by promoting the inclusion of GOLIM4 exon 7, subsequently enhancing the proliferation and migration of NPC cells in vitro and facilitating CDX model growth in vivo. 32 In laryngeal cancer cells (Tu177 and Hep2), the upregulated lncRNA ZFAS1 binds to and upregulates RBFOX2 expression. Elevated RBFOX2 promotes the skipping of MENA exon 11a, ultimately stimulating proliferation, EMT, and invasion of laryngeal cancer cells. 46 In ovarian cancer, the lncRNA MALAT1 has been identified to enhance the expression of RBFOX2, subsequently suppressing apoptosis in ovarian cancer cells (HEY and OVARY1847). 104 Moreover, in the Ewing's sarcoma cell line (A673), RBFOX2 has been found to bind to ADD3 (a phenotypic driver of Ewing's sarcoma) pre‐mRNA. This interaction inhibits the inclusion of ADD3 exon 14, promoting the mesenchymal phenotype of Ewing's sarcoma cells. 44 These insights illuminate the intricate regulatory roles of RBFOX2 in different cancer contexts, providing valuable clues for targeted therapeutic interventions.

In contrast to these findings, some studies reveal that RBFOX2 can also exert inhibitory effects on tumour proliferation and invasion. For example, CD47, a receptor widely expressed in cancer cells facilitating evasion from immune system phagocytosis, experiences downregulation of splice isoforms through RBFOX2 in paediatric AML‐derived HSCs/HPCs, subsequently impeding tumour proliferation. 6 In PDAC cells (BxPC3), RBFOX2 has been identified as a promoter of MPRIP exon 23 inclusion. This inclusion enhances the capacity of MPRIP to inhibit RHOA through its RHO GTPase activating protein function, thereby suppressing tumour cell invasion, migration and in vivo metastasis as demonstrated in a PDX model. 51 Recent studies have found that in PDAC, downregulation of RBFOX2 can promote skipping of ABI1 exon 9, causing ABI1 to redistribute from the cytoplasm to the cell periphery. ABI1 at the periphery participates in assembling the WAVE signalling complex, promoting actin polymerisation and cytoskeleton remodeling by activating the Arp2/3 complex, thereby enhancing cell migration and invasion, and causing chemotherapy resistance. 100 , 109 These findings underscore the significant impact of RBFOX2‐mediated splicing regulation on the invasive behaviour of PDAC cells, providing potential avenues for therapeutic intervention.

Moreover, in GBM cells (U87MG), RBFOX2 counters SON by promoting PTBP2 exon 10 inclusion, resulting in inhibition of GBM cell proliferation and maintenance of tumour stem cells. 43 K63‐mediated ubiquitination is a specific type of protein modification process that typically occurs at the Lys63 site of the protein. 110 Unlike other types of ubiquitination (such as K48 ubiquitination), K63‐linked ubiquitination usually does not lead to the degradation of the modified protein but forms a persistent modification, playing a regulatory role in the cell. 111 Notably, the latest study by Li et al. explains a new role of RBFOX2 in GBM and highlights a novel phenomenon of K63‐mediated ubiquitination. Specifically, in GBM, the upregulation of FBXO7 can dimethylate Arg341 and Arg441 of RBFOX2 through PRMT5, followed by K63‐linked ubiquitination at Lys249. This modification enhances RBFOX2 stability and upregulation. The upregulated RBFOX2 promotes the inclusion of FoxM1 exon Va, making FoxM1 more susceptible to MEK1 phosphorylation, thereby increasing the levels of CD44, CD9 and ID1, ultimately leading to GBM stem cell self‐renewal and mesenchymal transformation. 103 Targeting the FBXO7‒RBFOX2 axis could become a potential strategy for GBM treatment. In malignant gliomas, RBFOX2 acts as a reader, recognising hm5C introduced by NSUN5 and TET2 on CTNNB1 caRNA, leading to CTNNB1 caRNA degradation. CTNNB1 encodes the β‐catenin protein. This process inhibits the β‐catenin signalling pathway, blocking the phagocytosis of tumour‐associated macrophages and resulting in strong immune evasion in malignant gliomas. 30

Fascinatingly, in endometrial cancer cell lines (KLE and Ishikawa), circRAPGEF5 has been found to competitively bind to the CTD of RBFOX2, specifically residues 266−367. This interaction prevents RBFOX2 from binding to TFRC pre‐mRNA, showcasing the intricate regulatory network governing RNA splicing in cancer cells. This event hinders the inclusion of TFRC exon 4, rendering ferroptosis resistance in endometrial cancer cells. 45

6.3 RBFOX2‐mediated splicing regulation in anticancer drug resistance

The emergence of drug resistance in tumour cells poses a significant obstacle to the effectiveness of chemotherapy and contributes to unfavourable prognoses. 112 Recent studies have uncovered the pivotal role of stabilising the splicing activity of RBFOX2 in conferring resistance to anticancer therapies. 6

TAM, a widely used selective estrogen receptor modulator, plays a critical role in BrC treatment. 113 Notably, statistics reveal that 2 years of TAM therapy can provide long‐term therapeutic benefits lasting up to 20 years for premenopausal BrC patients with estrogen receptor‐positive (ER+) tumours. 114 RBFOX2's role in interfering with the transcriptional activity of steroid receptors, including the modulation of ligands like TAM, was first reported in 2002. 11 The RBFOX2‐DN isoform, a major negative regulator of RBFOX2's canonical splicing activity, may potentially underlie resistance to other steroid receptor modulators such as Raloxifene, 115 Fulvestrant 116 and Antiandrogens 117 in ER+ BrC. 118

Rebecsinib, a small molecule exhibiting the ability to counteract aberrant gene overediting prompted by malignancies, presents a hopeful avenue for addressing drug resistance and relapse in patients with high‐risk myelofibrosis and secondary AML driven by leukaemia stem cells. 119 In cord‐blood‐derived hematopoietic stem and progenitor cells, downregulation‐induced splicing dysregulation of RBFOX2 sensitises cells to Rebecsinib treatment, as demonstrated in both colony survival and colony replating assays. 6

7 TARGETING RBFOX2: UNRAVELING THERAPEUTIC STRATEGIES FOR DISEASE MODULATION

RBFOX2, with its multifaceted role in alternative splicing, emerges as a crucial player in the pathogenesis of CVDs, cancers and other disorders, notably contributing to treatment resistance in malignant tumours. Consequently, targeting RBFOX2 holds significant promise as a cancer therapy. Despite this potential, there is a conspicuous absence of reports on drugs specifically designed to target RBFOX2. Traditionally, RBPs have posed challenges as drug targets. 120 However, recent advancements in protein degradation techniques, such as proteolysis‐targeting chimeras (PROTAC), have opened new avenues (Figure 5). 121 RNA‐PROTAC, comprising a genetically encoded RNA scaffold and a synthetic bifunctional small molecule, orchestrates the degradation of target proteins through ubiquitin‐proteasome‐mediated pathways. 122 Studies indicate that Aptamer‐based RNA‐PROTAC effectively induces the degradation of RBFOX1, a close homologue of RBFOX2, by targeting the specific RBFOX1 binding sequence (‒UGCAUGU‒). 123 Given the structural similarity between RBFOX1 and RBFOX2 in their binding sequences (‒UGCAUG‒), Aptamer‐based RNA‐PROTAC presents a promising avenue for RBFOX2 degradation.

FIGURE 5 RNA‐PROTAC: targeted degradation strategy extending to RBFOX proteins. RNA‐PROTAC consists of a genetically encoded RNA scaffold (containing an aptamer, linker and a RNA consensus binding element [RCBE]) and a synthetic bifunctional small molecule (one end binds the RNA scaffold and the other end binds E3 ubiquitin ligase). When the RCBE of RNA‐PROTAC contains the RNA‐binding fox‐1 homologue 1 (RBFOX1) binding sequence (UGCAUGU), RBFOX1 can bind to the RNA scaffold of the RNA‐PROTAC. At the same time, the bifunctional small molecules on RNA‐PROTAC can recruit E3 ubiquitin ligase to the RNA scaffold in a non‐covalent manner. The recruited E3 ubiquitin ligase specifically induces the ubiquitination of the target protein (i.e., RBFOX1) and its degradation through the ubiquitin‒proteasome pathway. This targeting method is also expected to be extended to RBFOX2. PROTAC, proteolysis targeting chimera; RCBE, RNA consensus binding element; Ub, ubiquitin. Created with BioRender.com.

Additionally, targeting upstream genes that influence RBFOX2 expression provides an alternative strategy. Notably, NEK2, a cancer‐associated factor linked to tumour progression and treatment resistance, promotes the premesenchymal splicing pattern of TNBC cells by upregulating RBFOX2 expression. 7 Despite the therapeutic potential of NEK2, no clinically approved NEK2‐targeting drugs exist. T‐1101 tosylate, a synthetic compound, induces NEK2 degradation and has shown anti‐tumour activity in HCC and BrC models. 124 Promisingly, T‐1101 tosylate has progressed to phase I clinical trials as an orally administered anticancer agent. 124 Moreover, imidazo pyridine derivatives, including MBM‐55 and 28e, have exhibited potent inhibitory effects on NEK2. 124 These compounds inhibit NEK2 activity by forming conserved hydrogen bonds, effectively impeding the proliferation of diverse tumour cells, including those in BrC, HCC and CRC. 125 , 126

As research into RBFOX2‐related diseases deepens, the development of therapies targeting RBFOX2 becomes increasingly urgent and promising. Currently, RBFOX2‐targeted research remains exploratory, with no publicised outcomes. However, with ongoing research, it is anticipated that RBFOX2‐targeted therapies will progress to clinical applications, offering improved prognoses for patients in need.

8 CONCLUDING REMARKS

Alternative splicing of RNA is pivotal for modulating various isoforms of downstream genes. Among RBPs, the RBFOX family, particularly RBFOX2, plays a crucial role in alternative RNA splicing, impacting diseases such as cancer and heart disease. RBFOX2 has emerged as a diagnostic marker in cancer and a potential therapeutic target. Moving forward, RBFOX2 assumes a multifaceted role extending beyond mere disease involvement. Notably, it plays a crucial part in growth, development and maintenance of bodily homeostasis by modulating tissue‐specific alternative splicing. 127 For instance, Rbfox2 neural crest‐specific deletion mice, constructed using the Cre‐LoxP recombinase system, develop craniofacial malformations such as cleft palate due to dysregulation of the Rbfox2‐TGF‐β‐Tak1 signalling axis during development. This suggests that RBFOX2 expression defects are key predisposing factors for neural crest developmental defects. 128 Moreover, in the murine liver, Rbfox2 orchestrates cholesterol homeostasis by governing the alternative splicing of Scarb1. These findings underscore the intricate regulatory functions of RBFOX2 in diverse physiological processes. 52

Although RBFOX2 expression disorders have been found in various diseases, the limitations of selected experimental analysis methods and research entry points mean that most results only indicate a statistical association between RBFOX2 and disease development. The causal relationship between RBFOX2 dysregulation and disease progression cannot yet be confirmed. Currently, we can only assert that RBFOX2 disorders are key predisposing factors for HLHS and neural crest developmental defects. Future studies could involve functional experiments in the laboratory, such as gene editing technologies (meganuclease, zinc‐finger nuclease [ZFN], transcription activator‐like effector nuclease [TALEN] or CRISPR/Cas9), to artificially regulate the target gene and observe its effects on cells or model animals. Fully exploring the causal relationship between RBFOX2 dysregulation and disease development will greatly enhance our understanding of disease pathogenesis and aid in developing new treatments and preventive measures.

Current basic research has unveiled the initial understanding of how RBFOX2 regulates alternative RNA splicing. Despite this progress, the full‐length structure of RBFOX family proteins remains elusive, limiting in‐depth exploration. Future studies employing advanced techniques such as nuclear magnetic resonance or cryo‐electron microscopy are poised to reveal the complete molecular structure of RBFOX2, expanding our comprehension significantly.

Protein post‐translational modifications (PTMs), including potential phosphorylation and methylation sites within RBFOX2, are areas ripe for investigation. These PTMs likely influence RBFOX2 function and disease development. Additionally, RBFOX2 exhibits multiple isoforms regulated by alternative splicing. While existing research predominantly focuses on overall RBFOX2 expression, understanding specific isoform expression could resolve the current controversies. Future exploration of PTMs and RBFOX2 isoforms promises a comprehensive understanding of its role in cancer and other diseases.

Given its diverse roles, particularly in malignancies, targeting RBFOX2 emerges as a pivotal strategy for translating research into clinical applications. Innovative technologies such as RNA‐PROTAC and NEK2 inhibitors (such as T‐1101 tosylate, MBM‐55 and 28e) offer promising avenues for targeted degradation and reduction of RBFOX2 levels. With ongoing advancements, RBFOX2‐related research is poised to enhance diagnostic accuracy, prognostic prediction and therapeutic efficacy in the near future.

AUTHOR CONTRIBUTIONS

Conceptualisation, writing—original draft and visualisation: Jinze Shen. Writing—original draft and visualisation: Jianqiao Shentu. Visualisation; Chenming Zhong and Qiankai Huang. Conceptualisation, writing—review and editing and funding acquisition: Shiwei Duan.

CONFLICT OF INTEREST STATEMENT

The authors declare they have no conflicts of interest.

ETHICS STATEMENT

Not applicable.

Supporting information

Supporting information

ACKNOWLEDGEMENTS

The authors would like to express their sincere gratitude for the support provided by the Qiantang Scholars Fund in Hangzhou City University (grant no. 210000‐581835) for this study.

DATA AVAILABILITY STATEMENT

Not applicable.
==== Refs
REFERENCES

1 He S , Valkov E , Cheloufi S , Murn J . The nexus between RNA‐binding proteins and their effectors. Nat Rev Genet. 2023;24 (5 ):276‐294.36418462
2 Corley M , Burns MC , Yeo GW . How RNA‐binding proteins interact with RNA: molecules and mechanisms. Mol Cell. 2020;78 (1 ):9‐29.32243832
3 Xu W , Biswas J , Singer RH , Rosbash M . Targeted RNA editing: novel tools to study post‐transcriptional regulation. Mol Cell. 2022;82 (2 ):389‐403.34739873
4 Conboy JG . Developmental regulation of RNA processing by Rbfox proteins. Wiley Interdiscip Rev RNA. 2017;8 (2 ).
5 Jin Y , Suzuki H , Maegawa S , et al. A vertebrate RNA‐binding protein Fox‐1 regulates tissue‐specific splicing via the pentanucleotide GCAUG. Embo J. 2003;22 (4 ):905‐912.12574126
6 van der Werf I , Mondala PK , Steel SK , et al. Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells. Cell Rep Med. 2023;4 (3 ):100962.36889320
7 Naro C , De Musso M , Delle Monache F , Panzeri V , de la Grange P , Sette C . The oncogenic kinase NEK2 regulates an RBFOX2‐dependent pro‐mesenchymal splicing program in triple‐negative breast cancer cells. J Exp Clin Cancer Res. 2021;40 (1 ):397.34930366
8 Hu J , Gao C , Wei C , et al. RBFox2‐miR‐34a‐Jph2 axis contributes to cardiac decompensation during heart failure. Proc Natl Acad Sci U S A. 2019;116 (13 ):6172‐6180.30867288
9 Danan‐Gotthold M , Golan‐Gerstl R , Eisenberg E , Meir K , Karni R , Levanon EY . Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Res. 2015;43 (10 ):5130‐5144.25908786
10 Cao J , Verma SK , Jaworski E , et al. RBFOX2 is critical for maintaining alternative polyadenylation patterns and mitochondrial health in rat myoblasts. Cell Rep. 2021;37 (5 ):109910.34731606
11 Norris JD , Fan D , Sherk A , McDonnell DP . A negative coregulator for the human ER. Mol Endocrinol. 2002;16 (3 ):459‐468.11875103
12 Auweter SD , Fasan R , Reymond L , et al. Molecular basis of RNA recognition by the human alternative splicing factor Fox‐1. Embo J. 2006;25 (1 ):163‐173.16362037
13 Kuroyanagi H . Fox‐1 family of RNA‐binding proteins. Cell Mol Life Sci. 2009;66 (24 ):3895‐3907.19688295
14 Lambert N , Robertson A , Jangi M , McGeary S , Sharp PA , Burge CB . RNA Bind‐n‐Seq: quantitative assessment of the sequence and structural binding specificity of RNA binding proteins. Mol Cell. 2014;54 (5 ):887‐900.24837674
15 Damianov A , Ying Y , Lin CH , et al. Rbfox proteins regulate splicing as part of a large multiprotein complex LASR. Cell. 2016;165 (3 ):606‐619.27104978
16 Meng EC , Goddard TD , Pettersen EF , et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 2023;32 (11 ):e4792.37774136
17 Kim KK , Yang Y , Zhu J , Adelstein RS , Kawamoto S . Rbfox3 controls the biogenesis of a subset of microRNAs. Nat Struct Mol Biol. 2014;21 (10 ):901‐910.25240799
18 Park C , Choi S , Kim YE , et al. Stress granules contain Rbfox2 with cell cycle‐related mRNAs. Sci Rep. 2017;7 (1 ):11211.28894257
19 Kedersha N , Stoecklin G , Ayodele M , et al. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol. 2005;169 (6 ):871‐884.15967811
20 Lee JA , Damianov A , Lin CH , et al. Cytoplasmic Rbfox1 regulates the expression of synaptic and autism‐related genes. Neuron. 2016;89 (1 ):113‐128.26687839
21 Nakahata S , Kawamoto S . Tissue‐dependent isoforms of mammalian Fox‐1 homologs are associated with tissue‐specific splicing activities. Nucleic Acids Res. 2005;33 (7 ):2078‐2089.15824060
22 Damianov A , Black DL . Autoregulation of Fox protein expression to produce dominant negative splicing factors. RNA. 2010;16 (2 ):405‐416.20042473
23 Choi S , Cho N , Kim KK . Non‐canonical splice junction processing increases the diversity of RBFOX2 splicing isoforms. Int J Biochem Cell Biol. 2022;144 :106172.35124219
24 Cho N , Kim JO , Lee S , et al. Alternative splicing induces cytoplasmic localization of RBFOX2 protein in calcific tendinopathy. Exp Mol Pathol. 2019;109 :36‐41.31128090
25 Wenzel M , Schüle M , Casanovas S , Strand D , Strand S , Winter J . Identification of a classic nuclear localization signal at the N terminus that regulates the subcellular localization of Rbfox2 isoforms during differentiation of NMuMG and P19 cells. FEBS Lett. 2016;590 (24 ):4453‐4460.27859055
26 Misra C , Bangru S , Lin F , et al. Aberrant expression of a non‐muscle RBFOX2 isoform triggers cardiac conduction defects in myotonic dystrophy. Dev Cell. 2020;52 (6 ):748‐763.e6.32109384
27 Ying Y , Wang XJ , Vuong CK , Lin CH , Damianov A , Black DL . Splicing activation by Rbfox requires self‐aggregation through its tyrosine‐rich domain. Cell. 2017;170 (2 ):312‐323.e10.28708999
28 Wei C , Xiao R , Chen L , et al. RBFox2 binds nascent RNA to globally regulate polycomb complex 2 targeting in mammalian genomes. Mol Cell. 2016;62 (6 ):875‐889.27211866
29 Dou X , Xiao Y , Shen C , et al. RBFOX2 recognizes N(6)‐methyladenosine to suppress transcription and block myeloid leukaemia differentiation. Nat Cell Biol. 2023;25 (9 ):1359‐1368.37640841
30 Wu R , Sun C , Chen X , et al. NSUN5/TET2‐directed chromatin‐associated RNA modification of 5‐methylcytosine to 5‐hydroxymethylcytosine governs glioma immune evasion. Proc Natl Acad Sci U S A. 2024;121 (14 ):e2321611121.38547058
31 Davidovich C , Zheng L , Goodrich KJ , Cech TR . Promiscuous RNA binding by Polycomb repressive complex 2. Nat Struct Mol Biol. 2013;20 (11 ):1250‐1257.24077223
32 Liu J , Gao M , He J , et al. The RNA m(6)A reader YTHDC1 silences retrotransposons and guards ES cell identity. Nature. 2021;591 (7849 ):322‐326.33658714
33 Marasco LE , Kornblihtt AR . The physiology of alternative splicing. Nat Rev Mol Cell Biol. 2023;24 (4 ):242‐254.36229538
34 Kim KK , Adelstein RS , Kawamoto S . Isoform‐specific proteasomal degradation of Rbfox3 during chicken embryonic development. Biochem Biophys Res Commun. 2014;450 (4 ):1662‐1667.25044120
35 Gehman LT , Meera P , Stoilov P , et al. The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function. Genes Dev. 2012;26 (5 ):445‐460.22357600
36 Zhou D , Couture S , Scott MS , Elela SA. RBFOX2 alters splicing outcome in distinct binding modes with multiple protein partners. Nucleic Acids Res. 2021;49 (14 ):8370‐8383.34244793
37 Zhou Y , Fan J , Zhu H , et al. Aberrant splicing induced by dysregulated Rbfox2 produces enhanced function of Ca(V)1.2 calcium channel and vascular myogenic tone in hypertension. Hypertension. 2017;70 (6 ):1183‐1192.28993448
38 Gu M , Zhao Y , Wang H , et al. Suppression of RBFox2 by multiple miRNAs in pressure overload‐induced heart failure. Int J Mol Sci. 2023;24 (2 ):1283.36674797
39 Vecellio Reane D , Cerqua C , Sacconi S , Salviati L , Trevisson E , Raffaello A . The splicing of the mitochondrial calcium uniporter genuine activator MICU1 is driven by RBFOX2 splicing factor during myogenic differentiation. Int J Mol Sci. 2022;23 (5 ):2517.35269658
40 Cao J , Routh AL , Kuyumcu‐Martinez MN . Nanopore sequencing reveals full‐length Tropomyosin 1 isoforms and their regulation by RNA‐binding proteins during rat heart development. J Cell Mol Med. 2021;25 (17 ):8352‐8362.34302435
41 Wan X , Belanger K , Widen SG , Kuyumcu‐Martinez MN , Garg NJ . Genes of the cGMP‐PKG‐Ca(2+) signaling pathway are alternatively spliced in cardiomyopathy: role of RBFOX2. Biochim Biophys Acta Mol Basis Dis. 2020;1866 (3 ):165620.31778749
42 Cooper AM , Nutter CA , Kuyumcu‐Martinez MN , Wright CW . Alternative splicing of the aryl hydrocarbon receptor nuclear translocator (ARNT) is regulated by RBFOX2 in lymphoid malignancies. Mol Cell Biol. 2022;42 (5 ):e0050321.35404107
43 Kim JH , Jeong K , Li J , et al. SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity. Nat Commun. 2021;12 (1 ):5551.34548489
44 Saulnier O , Guedri‐Idjouadiene K , Aynaud MM , et al. ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS‐FLI1 oncogenic fusion. Nucleic Acids Res. 2021;49 (9 ):5038‐5056.34009296
45 Zhang J , Chen S , Wei S , et al. CircRAPGEF5 interacts with RBFOX2 to confer ferroptosis resistance by modulating alternative splicing of TFRC in endometrial cancer. Redox Biol. 2022;57 :102493.36182807
46 Lu B , Li X , Miao W , et al. LncRNA ZFAS1 promotes laryngeal cancer progression through RBFOX2‐mediated MENA alternative splicing. Environ Toxicol. 2023;38 (3 ):522‐533.36336961
47 Londero M , Gallo A , Cattaneo C , et al. NF‐YAl drives EMT in Claudin(low) tumours. Cell Death Dis. 2023;14 (1 ):65.36707502
48 Choi S , Lee HS , Cho N , et al. RBFOX2‐regulated TEAD1 alternative splicing plays a pivotal role in Hippo‐YAP signaling. Nucleic Acids Res. 2022;50 (15 ):8658‐8673.35699208
49 Lu Y , Xu W , Ji J , et al. Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. Hepatology. 2015;62 (4 ):1122‐1131.26058814
50 Nakura T , Ozoe A , Narita Y , et al. Rbfox2 mediates exon 11 inclusion in insulin receptor pre‐mRNA splicing in hepatoma cells. Biochimie. 2021;187 :25‐32.34022289
51 Jbara A , Lin KT , Stossel C , et al. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer. Nature. 2023;617 (7959 ):147‐153.36949200
52 Paterson HAB , Yu S , Artigas N , et al. Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice. Nat Metab. 2022;4 (12 ):1812‐1829.36536133
53 Seth P , Yeowell HN . Fox‐2 protein regulates the alternative splicing of scleroderma‐associated lysyl hydroxylase 2 messenger RNA. Arthritis Rheum. 2010;62 (4 ):1167‐1175.20131247
54 Verma SK , Deshmukh V , Nutter CA , et al. Rbfox2 function in RNA metabolism is impaired in hypoplastic left heart syndrome patient hearts. Sci Rep. 2016;6 :30896.27485310
55 Supadmanaba IGP , Mantini G , Randazzo O , et al. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. Epigenetics. 2022;17 (4 ):381‐404.34057028
56 Li P , Qin D , Chen T , et al. Dysregulated Rbfox2 produces aberrant splicing of Ca(V)1.2 calcium channel in diabetes‐induced cardiac hypertrophy. Cardiovasc Diabetol. 2023;22 (1 ):168.37415128
57 Gallagher TL , Arribere JA , Geurts PA , et al. Rbfox‐regulated alternative splicing is critical for zebrafish cardiac and skeletal muscle functions. Dev Biol. 2011;359 (2 ):251‐261.21925157
58 Yin QF , Yang L , Zhang Y , et al. Long noncoding RNAs with snoRNA ends. Mol Cell. 2012;48 (2 ):219‐230.22959273
59 Yang Y , Lee GC , Nakagaki‐Silva E , et al. Cell‐type specific regulator RBPMS switches alternative splicing via higher‐order oligomerization and heterotypic interactions with other splicing regulators. Nucleic Acids Res. 2023;51 (18 ):9961‐9982.37548402
60 Weischenfeldt J , Waage J , Tian G , et al. Mammalian tissues defective in nonsense‐mediated mRNA decay display highly aberrant splicing patterns. Genome Biol. 2012;13 (5 ):R35.22624609
61 Jangi M , Boutz PL , Paul P , Sharp PA . Rbfox2 controls autoregulation in RNA‐binding protein networks. Genes Dev. 2014;28 (6 ):637‐651.24637117
62 Han J , An O , Ren X , et al. Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer. Nat Commun. 2022;13 (1 ):1793.35379802
63 García‐Moreno JF , Romão L . Perspective in alternative splicing coupled to nonsense‐mediated mRNA decay. Int J Mol Sci. 2020;21 (24 ):9424.33321981
64 Yang G , Huang SC , Wu JY . Regulated Fox‐2 isoform expression mediates protein 4.1R splicing during erythroid differentiation. Blood. 2008;111 (1 ):392‐401.17715393
65 Braeutigam C , Rago L , Rolke A , Waldmeier L , Christofori G , Winter J . The RNA‐binding protein Rbfox2: an essential regulator of EMT‐driven alternative splicing and a mediator of cellular invasion. Oncogene. 2014;33 (9 ):1082‐1092.23435423
66 Van Nostrand EL , Freese P , Pratt GA , et al. A large‐scale binding and functional map of human RNA‐binding proteins. Nature. 2020;583 (7818 ):711‐719.32728246
67 Singh RK , Kolonin AM , Fiorotto ML , Cooper TA . Rbfox‐splicing factors maintain skeletal muscle mass by regulating Calpain3 and proteostasis. Cell Rep. 2018;24 (1 ):197‐208.29972780
68 Wei C , Qiu J , Zhou Y , et al. Repression of the central splicing regulator RBFox2 is functionally linked to pressure overload‐induced heart failure. Cell Rep. 2015;10 (9 ):1521‐1533.25753418
69 Homsy J , Zaidi S , Shen Y , et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science. 2015;350 (6265 ):1262‐1266.26785492
70 Krach F , Wheeler EC , Regensburger M , et al. Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis. Acta Neuropathol. 2022;144 (3 ):413‐435.35778567
71 Leong DP , Joseph PG , McKee M , et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circ Res. 2017;121 (6 ):695‐710.28860319
72 McKean DM , Homsy J , Wakimoto H , et al. Loss of RNA expression and allele‐specific expression associated with congenital heart disease. Nat Commun. 2016;7 :12824.27670201
73 Nutter CA , Jaworski EA , Verma SK , et al. Dysregulation of RBFOX2 is an early event in cardiac pathogenesis of diabetes. Cell Rep. 2016;15 (10 ):2200‐2213.27239029
74 Ajoolabady A , Chiong M , Lavandero S , Klionsky DJ , Ren J . Mitophagy in cardiovascular diseases: molecular mechanisms, pathogenesis, and treatment. Trends Mol Med. 2022;28 (10 ):836‐849.35879138
75 Walsh R , Offerhaus JA , Tadros R , Bezzina CR . Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. Nat Rev Cardiol. 2022;19 (3 ):151‐167.34526680
76 Reynolds JO , Chiang DY , Wang W , et al. Junctophilin‐2 is necessary for T‐tubule maturation during mouse heart development. Cardiovasc Res. 2013;100 (1 ):44‐53.23715556
77 Hofmann F , Flockerzi V , Kahl S , Wegener JW . L‐type CaV1.2 calcium channels: from in vitro findings to in vivo function. Physiol Rev. 2014;94 (1 ):303‐326.24382889
78 Xue GL , Li DS , Wang ZY , et al. Interleukin‐17 upregulation participates in the pathogenesis of heart failure in mice via NF‐kappaB‐dependent suppression of SERCA2a and Cav1.2 expression. Acta Pharmacol Sin. 2021;42 (11 ):1780‐1789.33589793
79 Zhao Z , Wen H , Fefelova N , et al. Revisiting the ionic mechanisms of early afterdepolarizations in cardiomyocytes: predominant by Ca waves or Ca currents? Am J Physiol Heart Circ Physiol. 2012;302 (8 ):H1636‐H1644.22307670
80 Tang ZZ , Hong X , Wang J , Soong TW . Signature combinatorial splicing profiles of rat cardiac‐ and smooth‐muscle Cav1.2 channels with distinct biophysical properties. Cell Calcium. 2007;41 (5 ):417‐428.16979758
81 Wang J , Thio SS , Yang SS , et al. Splice variant specific modulation of CaV1.2 calcium channel by galectin‐1 regulates arterial constriction. Circ Res. 2011;109 (11 ):1250‐1258.21998324
82 Fici P , Gallerani G , Morel AP , et al. Splicing factor ratio as an index of epithelial‒mesenchymal transition and tumor aggressiveness in breast cancer. Oncotarget. 2017;8 (2 ):2423‐2436.27911856
83 Nystoriak MA , Murakami K , Penar PL , Wellman GC . Ca(v)1.2 splice variant with exon 9* is critical for regulation of cerebral artery diameter. Am J Physiol Heart Circ Physiol. 2009;297 (5 ):H1820‐1828.19717733
84 Wu W , Ziemann M , Huynh K , et al. Activation of Hippo signaling pathway mediates mitochondria dysfunction and dilated cardiomyopathy in mice. Theranostics. 2021;11 (18 ):8993‐9008.34522223
85 Zhuang L , Jia K , Chen C , et al. DYRK1B–STAT3 drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics. Circulation. 2022;145 (11 ):829‐846.35235343
86 Graham BH , Waymire KG , Cottrell B , Trounce IA , MacGregor GR , Wallace DC . A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet. 1997;16 (3 ):226‐234.9207786
87 Fan M , Zhang J , Tsai CW , et al. Structure and mechanism of the mitochondrial Ca(2+) uniporter holocomplex. Nature. 2020;582 (7810 ):129‐133.32494073
88 Singh RK , Xia Z , Bland CS , et al. Rbfox2‐coordinated alternative splicing of Mef2d and Rock2 controls myoblast fusion during myogenesis. Mol Cell. 2014;55 (4 ):592‐603.25087874
89 Runfola V , Sebastian S , Dilworth FJ , Gabellini D . Rbfox proteins regulate tissue‐specific alternative splicing of Mef2D required for muscle differentiation. J Cell Sci. 2015;128 (4 ):631‐637.25609712
90 Verma SK , Deshmukh V , Liu P , et al. Reactivation of fetal splicing programs in diabetic hearts is mediated by protein kinase C signaling. J Biol Chem. 2013;288 (49 ):35372‐35386.24151077
91 Liu L , Kryvokhyzha D , Rippe C , et al. Myocardin regulates exon usage in smooth muscle cells through induction of splicing regulatory factors. Cell Mol Life Sci. 2022;79 (8 ):459.35913515
92 Gazzara MR , Mallory MJ , Roytenberg R , et al. Ancient antagonism between CELF and RBFOX families tunes mRNA splicing outcomes. Genome Res. 2017;27 (8 ):1360‐1370.28512194
93 Dasgupta T , Ladd AN . The importance of CELF control: molecular and biological roles of the CUG‐BP, Elav‐like family of RNA‐binding proteins. Wiley Interdiscip Rev RNA. 2012;3 (1 ):104‐121.22180311
94 Ferlay J , Colombet M , Soerjomataram I , et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103 :356‐387.30100160
95 van den Bosch QCC , Nguyen JQN , Brands T , et al. FOXD1 is a transcription factor important for uveal melanocyte development and associated with high‐risk uveal melanoma. Cancers (Basel). 2022;14 (15 ):3668.35954332
96 Xie S , Li Z , Zhong Y , et al. RBFOX2 confers tumor growth by PI3K/AKT and MAPK signaling in gastric cancer. Eur J Cancer Prev. 2023;32 (5 ):468‐477.37264873
97 Choi S , Sa M , Cho N , Kim KK , Park SH . Rbfox2 dissociation from stress granules suppresses cancer progression. Exp Mol Med. 2019;51 (4 ):1‐12.
98 Ahuja N , Ashok C , Natua S , et al. Hypoxia‐induced TGF‐β‒RBFOX2‒ESRP1 axis regulates human MENA alternative splicing and promotes EMT in breast cancer. NAR Cancer. 2020;2 (3 ):zcaa021.33089214
99 Mochizuki Y , Funayama R , Shirota M , et al. Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer. Int J Cancer. 2021;149 (10 ):1787‐1800.34346508
100 Maurin M , Ranjouri M , Megino‐Luque C , et al. RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing. Nat Commun. 2023;14 (1 ):8444.38114498
101 Ahuja N , Ashok C , Natua S , et al. Hypoxia‐induced TGF‐beta‐RBFOX2‐ESRP1 axis regulates human MENA alternative splicing and promotes EMT in breast cancer. NAR Cancer. 2020;2 (3 ):zcaa021.33089214
102 Ou X , Zhou X , Li J , et al. p53‐Induced LINC00893 regulates RBFOX2 stability to suppress gastric cancer progression. Front Cell Dev Biol. 2021;9 :796451.35127712
103 Li S , Chen Y , Xie Y , et al. FBXO7 confers mesenchymal properties and chemoresistance in glioblastoma by controlling Rbfox2‐mediated alternative splicing. Adv Sci. 2023;10 (33 ):e2303561.
104 Gordon MA , Babbs B , Cochrane DR , Bitler BG , Richer JK . The long non‐coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2‐mediated alternative splicing. Mol Carcinog. 2019;58 (2 ):196‐205.30294913
105 Chen Y , Zubovic L , Yang F , et al. Rbfox proteins regulate microRNA biogenesis by sequence‐specific binding to their precursors and target downstream Dicer. Nucleic Acids Res. 2016;44 (9 ):4381‐4395.27001519
106 Robertson AG , Rendina LM . Gadolinium theranostics for the diagnosis and treatment of cancer. Chem Soc Rev. 2021;50 (7 ):4231‐4244.33599224
107 Polyak K . Heterogeneity in breast cancer. J Clin Invest. 2011;121 (10 ):3786‐3788.21965334
108 Marusyk A , Polyak K . Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805 (1 ):105‐117.19931353
109 Innocenti M , Zucconi A , Disanza A , et al. Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat Cell Biol. 2004;6 (4 ):319‐327.15048123
110 Zhu G , Herlyn M , Yang X . TRIM15 and CYLD regulate ERK activation via lysine‐63‐linked polyubiquitination. Nat Cell Biol. 2021;23 (9 ):978‐991.34497368
111 Tracz M , Bialek W . Beyond K48 and K63: non‐canonical protein ubiquitination. Cell Mol Biol Lett. 2021;26 (1 ):1.33402098
112 Long L , Assaraf YG , Lei ZN , et al. Genetic biomarkers of drug resistance: a compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resist Updat. 2020;52 :100703.32599434
113 Bazvand F , Mahdizad Z , Mohammadi N , et al. Tamoxifen retinopathy. Surv Ophthalmol. 2023;68 (4 ):628‐640.36781026
114 Johansson A , Dar H , van ’t Veer LJ , et al. Twenty‐year benefit from adjuvant goserelin and tamoxifen in premenopausal patients with breast cancer in a controlled randomized clinical trial. J Clin Oncol. 2022;40 (35 ):4071‐4082.35862873
115 Hong S , Chang J , Jeong K , Lee W . Raloxifene as a treatment option for viral infections. J Microbiol. 2021;59 (2 ):124‐131.33527314
116 Sledge GW Jr , Toi M , Neven P , et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor‐positive, ERBB2‐negative breast cancer that progressed on endocrine therapy‐MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6 (1 ):116‐124.31563959
117 Desai K , McManus JM , Sharifi N . Hormonal therapy for prostate cancer. Endocr Rev. 2021;42 (3 ):354‐373.33480983
118 Arya AD , Wilson DI , Baralle D , Raponi M . RBFOX2 protein domains and cellular activities. Biochem Soc Trans. 2014;42 (4 ):1180‐1183.25110022
119 Crews LA , Ma W , Ladel L , et al. Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. Cell Stem Cell. 2023;30 (3 ):250‐263.e6.36803553
120 Julio AR , Backus KM . New approaches to target RNA binding proteins. Curr Opin Chem Biol. 2021;62 :13‐23.33535093
121 Békés M , Langley DR , Crews CM . PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21 (3 ):181‐200.35042991
122 Ghidini A , Cléry A , Halloy F , Allain FHT , Hall J . RNA‐PROTACs: degraders of RNA‐binding proteins. Angew Chem Int Ed Engl. 2021;60 (6 ):3163‐3169.33108679
123 Xu Y , Yuan Y , Fu DQ , et al. The aptamer‐based RNA‐PROTAC. Bioorg Med Chem. 2023;86 :117299.37137271
124 Chuang SH , Lee YE , Huang LYL , et al. Discovery of T‐1101 tosylate as a first‐in‐class clinical candidate for Hec1/Nek2 inhibition in cancer therapy. Eur J Med Chem. 2020;191 :112118.32113126
125 Xi JB , Fang YF , Frett B , et al. Structure‐based design and synthesis of imidazo[1,2‐a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem. 2017;126 :1083‐1106.28039836
126 Wang H , Chen Y , Gu X , et al. Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo[1,2‐a] pyridine derivatives as Nek2 inhibitors. Bioorg Med Chem. 2020;28 (23 ):115775.32992252
127 Zhang C , Zhang Z , Castle J , et al. Defining the regulatory network of the tissue‐specific splicing factors Fox‐1 and Fox‐2. Genes Dev. 2008;22 (18 ):2550‐2563.18794351
128 Cibi DM , Mia MM , Guna Shekeran S , et al. Neural crest‐specific deletion of Rbfox2 in mice leads to craniofacial abnormalities including cleft palate. Elife. 2019;8 :e45418.31241461
